Development and characterization of gastro-floating sustained-release capsule with improved bioavailability of levodopa

被引:0
作者
Hao Yuan
Zhengyu Zhang
Liandong Hu
机构
[1] Hebei University,Key Laboratory of Pharmaceutical Quality Control of Hebei Province, College of Pharmaceutical Sciences, Institute of Life Science and Green Development
来源
Drug Delivery and Translational Research | 2023年 / 13卷
关键词
Levodopa; Gastro-floating; Sustained-release capsules; Zero-level release; Pharmacokinetics;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:9 / 17
页数:8
相关论文
共 146 条
[1]  
Zhao R(2014)(6aR)-11-amino-N-propyl-noraporphine, a new dopamine D2 and serotonin 5-HT1A dual agonist, elicits potent antiparkinsonian action and attenuates levodopa-induced dyskinesia in a 6-OHDA-lesioned rat model of Parkinson’s disease Pharmacol Biochem Behav 124 204-210
[2]  
Lu W(2020)Anxiety: an ignored aspect of Parkinson’s disease lacking attention Biomed Pharmacother 131 110776-76
[3]  
Fang X(2021)Association of Helicobacter pylori treatment with Parkinsonism and related disorders: a systematic review and meta-analysis Life Sci 281 119767-62
[4]  
Guo L(2021)Parkinson’s disease and skin Parkinsonism Relat D 82 61-231
[5]  
Yang Z(2018)Mild hyperbaric oxygen inhibits the decrease of dopaminergic neurons in the substantia nigra of mice with MPTP-induced Parkinson’s disease Neurosci Res 132 58-1160
[6]  
Ye N(2021)Effects of vitamin B12, folate, and entacapone on homocysteine levels in levodopa-treated Parkinson’s disease patients: a randomized controlled study J Clin Neurosci 88 226-676
[7]  
Zhao J(1981)Dosage form design for improvement of bioavailability of levodopa V: absorption and metabolism of levodopa in intestinal segments of dogs J Pharm Sci 70 1157-59
[8]  
Liu Z(2021)Glutathione-decorated fluorescent carbon quantum dots for sensitive and selective detection of levodopa Anal Chim Acta 1165 338513-948
[9]  
Jia J(2019)Voltammetric amplified platform based on ionic liquid/NiO nanocomposite for determination of benserazide and levodopa[J] J Mol Liq 278 672-1100
[10]  
Zheng L(2009)Levodopa/carbidopa and entacapone in the treatment of Parkinson’s disease: efficacy, safety and patient preference Patient Prefer Adherence 3 51-1095